In yesterday’s Wall Street session, Amicus Therapeutics Inc. (NASDAQ:FOLD) shares traded at $13.60, down -0.33% from the previous session.
12 analysts cover Amicus Therapeutics Inc. (NASDAQ:FOLD), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $12.00, we find $16.00. Given the previous closing price of $13.65, this indicates a potential upside of 17.22 percent. FOLD stock price is now 10.72% away from the 50-day moving average and 14.44% away from the 200-day moving average. The market capitalization of the company currently stands at $3.89B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 5 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $15.90 as their price target over the next twelve months.
With the price target of $14, Morgan Stanley recently initiated with Equal-Weight rating for Amicus Therapeutics Inc. (NASDAQ: FOLD).
In other news, Crowley John F, Executive Chairman sold 6,044 shares of the company’s stock on Jul 17. The stock was sold for $81,263 at an average price of $13.45. Upon completion of the transaction, the Executive Chairman now directly owns 938,185 shares in the company, valued at $12.76 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 13, President & CEO Campbell Bradley L sold 6,800 shares of the business’s stock. A total of $85,091 was realized by selling the stock at an average price of $12.51. This leaves the insider owning 806,854 shares of the company worth $10.97 million. Insiders disposed of 1,123,535 shares of company stock worth roughly $15.28 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FOLD stock. A new stake in Amicus Therapeutics Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $30,599,000. GREAT LAKES ADVISORS, LLC invested $7,807,000 in shares of FOLD during the first quarter. In the first quarter, GHOST TREE CAPITAL, LLC acquired a new stake in Amicus Therapeutics Inc. valued at approximately $6,462,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in FOLD for approximately $5,292,000. GREAT POINT PARTNERS I LP purchased a new stake in FOLD valued at around $5,170,000 in the second quarter. In total, there are 320 active investors with 105.77% ownership of the company’s stock.
On Monday morning Amicus Therapeutics Inc. (NASDAQ: FOLD) stock kicked off with the opening price of $13.64. During the past 12 months, Amicus Therapeutics Inc. has had a low of $9.10 and a high of $13.85. As of last week, the company has a debt-to-equity ratio of 3.83, a current ratio of 2.90, and a quick ratio of 2.70. The fifty day moving average price for FOLD is $12.33 and a two-hundred day moving average price translates $11.90 for the stock.
The latest earnings results from Amicus Therapeutics Inc. (NASDAQ: FOLD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.15 by -0.03. This compares to -$0.30 EPS in the same period last year. The net profit margin was -60.60% and return on equity was -153.70% for FOLD. The company reported revenue of $86.27 million for the quarter, compared to $78.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.6 percent. For the current quarter, analysts expect FOLD to generate $89.87M in revenue.
Amicus Therapeutics Inc.(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
